Abstract
Acute liver failure as life threatening condition comprises a difficult diagnostic situation to evaluate potential outcomes and therapeutic options. Thus, prognostic indicators are urgently needed for evaluation of progression of liver injury, clinical outcome, prognosis, and for therapeutic response. Recently, circulating microRNA, in particular miR-122, was described as a potential biomarker of acute liver injury after intoxication of mice. Circulating microRNA (miRNA) molecules are very stable and RNase-resistant due to protein aggregation and vesicle enclosure. Since miRNA species are known to be associated with chronic liver damage or with liver cancer, circulating miRNA patterns are suggested to serve also as reporters for progression of acute liver failure. miRNA profiling analyses using PCR arrays or next generation sequencing, may achieve identification of miRNA species that are linked to the rapid progression of acute liver injury, to the outcome of liver failure, or to the therapeutic response. Therefore, circulating miRNAs are promising, non-invasive biomarkers of future diagnostic approaches. However, normalisation of circulating miRNA levels is essential and further standardisation of miRNA quantification assays is needed.
Introduction
Acute liver failure is a life-threatening liver disease characterized by a rapid and fulminant loss of liver function. Common causes of acute liver failure are viral hepatitis infection, mainly hepatitis A and B, and drug-induced liver intoxication (Canbay et al., 2005; Hadem et al., 2008; Ichai and Samuel, 2008, 2011; Lee, 2012). Acute liver failure demands urgent medical care, but initial symptoms of acute liver failure such as diarrhea, fatigue, and loss of appetite are rather unspecific and difficult to interpret (Renner, 2007). Rapid progression of liver malfunction is then accompanied by serious symptoms as ascites, hepatic encephalopathy, and coma. Sometimes, the acute liver failure can be reversed by valiant clinical intervention, but in many cases liver transplantation might be the only option of cure (Bernal et al., 2008; Ichai and Samuel, 2008; Lee, 2012). Thus, prognostic indicators are urgently needed for evaluation of progression of liver injury, clinical outcome, prognosis, and for therapeutic response. Recently, circulating microRNA is described as a novel tool to diagnose and monitor various diseases [summarized by Cortez and Calin (2009)].
MicroRNAs (miRNAs) are short noncoding, endogenous RNAs that regulate posttranscriptional gene expression by either RNA interference or inhibition of translational initiation and elongation (Bartel, 2004). Therefore, miRNAs are implicated in a widespread variety of cellular processes like differentiation, cell proliferation, and apoptosis (Miska, 2005; Bushati and Cohen, 2007). In human, more than thousand miRNAs are known (Kozomara and Griffiths-Jones, 2011). Mature miRNAs are formed in a step-wise process from larger primary transcripts (pri-miRNA), which are further processed, folding to hairpin structured precursor miRNA (pre-miRNA). The pre-miRNAs are exported from the nucleus, serving as substrates for the Dicer family of RNase III enzymes. One strand of the resulting short dsRNA guides the RNA-induced silencing complex (RISC) to its target mRNA (Zhao and Srivastava, 2007). Then, perfect complementary interaction of miRNAs with the untranslated region (UTR) of transcripts results in transcript degradation, whereas imperfect base pairing of miRNAs with the targeted UTR leads to translational repression (Zhao and Srivastava, 2007; Bartel, 2009).
In addition to the cellular function of miRNA in posttranscriptional gene repression, recent data collect evidence that miRNA also occur in extracellular compartments (Hunter et al., 2008; Mitchell et al., 2008). In our present review, we summarize the perspectives of circulating miRNAs to function as novel promising biomarkers of acute hepatitis.
Dysregulation of hepatic miR-122 after liver injury
miRNA expression profiles appear to be tissue-specific. Thus, miR-122 is highly expressed in hepatocytes, due to its liver-specific transcriptional regulation by hepatocyte nuclear transcription factors (HNF1α, HNF3β, and HNF4α) (Coulouarn et al., 2009; Xu et al., 2010). miR-122, comprising approximately 70% of total miRNA in the healthy liver, takes part in liver-specific functions such as cholesterol metabolism (Esau et al., 2006; Jopling, 2012). Interestingly, miR-122 is transcribed in a circadian fashion affecting gene expression pattern of a wide range of proteins (Gatfield et al., 2009). Whereas miR-122 interaction with the 3′ untranslated region (UTR) of various transcripts leads to gene repression, miR-122 binding to two target sites in the 5′-UTR of the HCV genome results in HCV-RNA genome stabilization and enhanced replication. Hence, the liver-specific miR-122 may contribute to HCV liver tropism at the level of translation (Henke et al., 2008; Jopling, 2008).
Dedifferentiation of hepatocytes during hepatocellular carcinogenesis is associated with the loss of miR-122 (Coulouarn et al., 2009; Burchard et al., 2010; Negrini et al., 2011). In addition, during, both, acute and chronic liver damages in response to various noxa such as viral infection, drug or alcohol intoxication, or heriditary disorders, miR-122 is markedly decreased in the injured liver. Thus, after non-alcoholic fat liver diseases (Cheung et al., 2008) as well as after chronic hepatitis C infection reduced hepatic miR-122 levels were observed (Sarasin-Filipowicz et al., 2009; Morita et al., 2011). However, whereas miRNA is decreased in the injured liver, recent reports pointed to increased levels of circulating miR-122 in the blood stream after acute liver injury-induced by paracetamol intoxication of mice (Wang et al., 2009).
miRNA released into the blood stream after liver disease
In serum from human patients suffering from prostate cancer, it was first described that miRNA occur also extracellularily (Hunter et al., 2008; Mitchell et al., 2008). Circulating miRNA are highly stable in serum and also RNase resistant (Figure 1A), due to protein aggregation and vesicle enclosure (Mitchell et al., 2008; Cortez and Calin, 2009; Chen et al., 2010). As vesicular structures embedding extracellular miRNA, apoptotic bodies, microvesicles (Hunter et al., 2008; Skog et al., 2008), and exosomes (Taylor and Gercel-Taylor, 2008) have been discussed (Figure 1B). Due to their high stability, they are ideal candidates considered as non-invasive diagnostic markers indicating progression and therapy outcome of disease. Accordingly, circulating miRNAs were detected in some other tumorigenic diseases such as ovarian (Lodes et al., 2009; Resnick et al., 2009), lung, and colorectal cancer (Chen et al., 2008; Ng et al., 2009) (for review please see Cortez and Calin, 2009). Furthermore, Vasilescu et al. revealed circulating miR-150 as a new prognostic marker of patients with sepsis and Wang et al. described prominent upregulation of serum miR-122 and miR-192 after acute hepatic intoxication by paracetamol in mice (Wang et al., 2009). In addition to miR-122 and miR-192, Zhou et al. identified miR-21, miR-223, miR-26a, miR-27a, and miR-801 in serum of patients with hepatocellular carcinoma (HCC) and proposed this miRNA panel as predictive markers of HCC. A comprehensive study on a wide cohort of patients with HBV or HCV based HCC revealed that high miR-25, let7f and primary miR-375 profiles only occurred in HCC-positive patients. Herein, increased miR-375 levels are shown to be specifically associated to HBV positive HCC (Li et al., 2010).
Figure 1
Importantly, miRNA panels in serum could not only be applied to differentiate between HCC and normal healthy donors, but also between HCC and cirrhosis (Zhou et al., 2011). Although miR-122 quantification of 68 serum samples of chronic HCV-positive patients was not normalized, the findings of Bihrer et al. definitively demonstrate that miR-122 correlated with alanine aminotransferase (ALT) values indicating liver inflammatory activity (Bihrer et al., 2011). Thus, circulating miRNAs are proposed as new biomarkers not only for tumorigenic, but also for inflammatory liver diseases.
Extracellular miRNAs in the blood stream are promising biomarkes of acute hepatitis
Previous findings in mice after acute intoxication revealed that miR-122 increased markedly in serum samples before liver transaminases were raised (Wang et al., 2009; Zhang et al., 2010). This is of particular interest, because miRNA might not only be released by hepatocellular destruction processes, but also by active secretory delivery into the blood stream (Figure 1C). Consequently, early increased levels of serum miR-122 in response to inflammatory stimuli have to be considered as better indicators of liver failure than determination of liver-specific enzymes such as ALT (Zhang et al., 2010; Wang et al., 2012). Interestingly, Bala et al. found that after acute paracetamol intoxication of mice, miR-122 and miR-155 were predominantly associated in protein aggregates, whereas after alcoholic liver disease these two miRNAs were mainly found in the vesicular fraction (Bala et al., 2012). In addition, Novellino et al. suggested that in 13 serum samples of patients with HBV infection, miRNA is mainly complexed with the Ago2 protein, which in turn binds the hepatitis B surface protein (Novellino et al., 2012).
In addition to the experiments on acutely intoxicated mice, first data are now available on human, showing high miR-122 levels after acute hepatitis in man (Starkey Lewis et al., 2011; Ding et al., 2012). The extracellular miR-122 levels in serum from patients with acetaminophen based acute liver injury were normalized using small nuclear (sn)U6 spliceosomal RNA which is so far the most commonly applied internal reference of circulating miRNA quantification (Table 1). Though snU6 RNA is proposed to be also released into the blood stream after cellular damage including liver parenchymal injury, this data interpretation may provide a primary impression of the role of miR-122 in human acute liver failure. However, Ji et al. found no change of miR-122 in 21 patients with HBV-induced acute-on-chronic liver failure, whereas miR-122 in patients with chronic HBV infection was even decreased in comparison to 12 healthy controls (Ji et al., 2011). These conflicting results might be due to diversity of study designs and technical approaches.
Table 1
| Potential miRNA biomarker | Human liver disease | Normalisation | Detection/quantification method | Message | Referencesb |
|---|---|---|---|---|---|
| High: miR-21, miR-192, −801 | HBV HCC HBV chronic (N ~ 1000) | miR-1228 | Microarray, Real Time PCR | Differentiation between healthy donors, chronic HBV, and HCC | Zhou et al., 2011 |
| Low: miR-26a, −27a, miR-122, −223, | |||||
| High: miR-25, −92a, let7f, miR-375 | HBV chronic, HCC (N ~ 150) | / | NGS, Real Time PCR | miR-375 is HBV specific and a HCC predictor | Li et al., 2010 |
| High: miR-122, miR-21, 223 | HBV chronic, HCC (N ~ 150) | miR-181aa | Relative Real Time PCR | Increase in chronic HBV and HCC | Xu et al., 2011 |
| miR-181ca | |||||
| High: miR-122 | HBV chronic (N = 83) | U6 RNA | Relative Real Time PCR | Increase of miR-122 | Zhang et al., 2010 |
| High: miR-885-5p | HBV chronic, cirrhotic, HCC (N > 100) | U6 RNA | Relative Real Time PCR | Increase in chronic, cirrhotic HBV and HCC | Gui et al., 2011 |
| High: miR-122 | HCV chronic (N = 68) | / | Relative Real Time PCR | Increase correlated with ALT | Bihrer et al., 2011 |
| High: miR-571 | Chronic HCV and alcohol (N = 67) | Spike-in RNA | Relative Real Time PCR | miR-571 reflects progression | Roderburg et al., 2012 |
| Low: miR-652 | |||||
| High: miR-122, −34 | HCV chronic (N = 34), NAFLD (N = 35) | Spike-in RNA | Absolute Real Time PCR | Correlation with ALT, inflammatory activity and fibrosis | Cermelli et al., 2011 |
| High: miR-122, −192 | Acute (POD) (N = 53) | U6 RNA | Real Time PCR | Increase correlated with ALT | Starkey Lewis et al., 2011 |
miRNAs as potential biomarkers for liver disease.
according to geNorm; POD: acetominophen overdose.
Unfortunately, we could not refer to all literature.
miRNA shown in bold: miRNA identified in serum samples by various reports.
For predictive use, standardisation in miRNA quantification is needed
Different methods are used to identify the pattern of miRNA in serum. Due to the very high sensitivity required for detection of circulating miRNA, Real Time PCR approaches are mostly carried out for screening as well as for validation of miRNA levels (Figure 2). Since miRNA are small templates, PCR needs a careful primer design and an elongation step of miRNA templates has to be combined to the reverse transcription before PCR amplification is started (Figure 3). For elongation of miRNA targets, either polyadenylation of miRNA is carried out (Shi and Chiang, 2005) or hairpin-looped primers are applied to the reverse transcription step leading to elongation of cDNA by the hairpin sequence (Chen et al., 2005) (Figure 3).
Figure 2
Figure 3
However, next generation sequencing (NGS) is also a valuable method to detect the pattern of circulating miRNAs followed by PCR quantification to validate data on a wide cohort of patients (Figure 2).
Although miR-122, miR-192, miR-21, and miR-34a are shown by most reports to be increased after experimental or human liver injury (Table 1), high variance and conflicting data exist about miRNA incidence in the blood stream upon different liver diseases. Kim et al. pointed out, that blood components that are co-purified with miRNA from serum or plasma highly affect efficiency of miRNA quantification by PCR (Kim et al., 2012). It is well-known that anti-coagulants in blood samples strongly inhibit Taq-polymerase, but plasma or serum sample volume, time until serum or plasma is prepared might also affect miRNA accessibility by Real Time PCR assays.
In addition, the accuracy of extracellular miRNA quantification highly depends on normalisation using an appropriate reference RNA. Thus, Xu et al. identified increased levels of circulating miR-122 and mir-92a as putative markers of chronic HBV infection after normalisation to endogenous miR-181 values, whereas Ji et al. observed decreasing levels of both miRNA after normalisation using snU6-RNA (Ji et al., 2011; Xu et al., 2011). snU6-RNA is mostly used as a reference. It is ubiquitously expressed in cells, but highly differs in the blood stream of different individuals (Qi et al., 2012). Furthermore, Ding et al. found that snU6-RNA is decreased after hepatocarcinogenesis (Ding et al., 2012). Hence, an internal standard for miRNA quantification is missing, so far. Therefore, the application of spike-in RNA is recommended in order to normalize errors in sample handling and extraction (Figure 2). Though miRNA are very stable molecules in serum or plasma, for better comparability and reproducibility in future studies, a well-standardized protocol is needed, in order to evaluate miRNAs as biomarkers for acute hepatitis.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
BalaS.PetrasekJ.MundkurS.CatalanoD.LevinI.WardJ.et al. (2012). Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology56, 1946–1957. 10.1002/hep.25873
2
BartelD. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell116, 281–297. 10.1016/S0092-8674(04)00045-5
3
BartelD. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell136, 215–233. 10.1016/j.cell.2009.01.002
4
BernalW.AuzingerG.SizerE.WendonJ. (2008). Intensive care management of acute liver failure. Semin. Liver Dis. 28, 188–200. 10.1055/s-2008-1073118
5
BihrerV.Friedrich-RustM.KronenbergerB.ForestierN.HaupenthalJ.ShiY.et al. (2011). Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 106, 1663–1669. 10.1038/ajg.2011.161
6
BurchardJ.ZhangC.LiuA. M.PoonR. T.LeeN. P.WongK. F.et al. (2010). microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol. Syst. Biol. 6:402. 10.1038/msb.2010.58
7
BushatiN.CohenS. M. (2007). microRNA functions. Annu. Rev. Cell Dev. Biol. 23, 175–205. 10.1146/annurev.cellbio.23.090506.123406
8
CanbayA.ChenS. Y.GieselerR. K.MalagoM.KarliovaM.GerkenG.et al. (2005). Overweight patients are more susceptible for acute liver failure. Hepatogastroenterology52, 1516–1520.
9
CermelliS.RuggieriA.MarreroJ. A.IoannouG. N.BerettaL. (2011). Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE6:e23937. 10.1371/journal.pone.0023937
10
ChenC.RidzonD. A.BroomerA. J.ZhouZ.LeeD. H.NguyenJ. T.et al. (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33:e179. 10.1093/nar/gni178
11
ChenC.SkogJ.HsuC. H.LessardR. T.BalajL.WurdingerT.et al. (2010). Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab. Chip10, 505–511. 10.1039/b916199f
12
ChenX.BaY.MaL.CaiX.YinY.WangK.et al. (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18, 997–1006. 10.1038/cr.2008.282
13
CheungO.PuriP.EickenC.ContosM. J.MirshahiF.MaherJ. W.et al. (2008). Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology48, 1810–1820. 10.1002/hep.22569
14
CortezM. A.CalinG. A. (2009). MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin. Biol. Ther. 9, 703–711. 10.1517/14712590902932889
15
CoulouarnC.FactorV. M.AndersenJ. B.DurkinM. E.ThorgeirssonS. S. (2009). Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene28, 3526–3536. 10.1038/onc.2009.211
16
DingX.DingJ.NingJ.YiF.ChenJ.ZhaoD.et al. (2012). Circulating microRNA-122 as a potential biomarker for liver injury. Mol. Med. Rep. 5, 1428–1432. 10.3892/mmr.2012.838
17
EsauC.DavisS.MurrayS. F.YuX. X.PandeyS. K.PearM.et al. (2006). miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3, 87–98. 10.1016/j.cmet.2006.01.005
18
GatfieldD.Le MartelotG.VejnarC. E.GerlachD.SchaadO.Fleury-OlelaF.et al. (2009). Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev. 23, 1313–1326. 10.1101/gad.1781009
19
GuiJ.TianY.WenX.ZhangW.ZhangP.GaoJ.et al. (2011). Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin. Sci. (Lond.)120, 183–193. 10.1042/CS20100297
20
HademJ.StiefelP.BahrM. J.TillmannH. L.RifaiK.KlempnauerJ.et al. (2008). Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. Clin. Gastroenterol. Hepatol. 6, 339–345. 10.1016/j.cgh.2007.12.039
21
HenkeJ. I.GoergenD.ZhengJ.SongY.SchuttlerC. G.FehrC.et al. (2008). microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 27, 3300–3310. 10.1038/emboj.2008.244
22
HunterM. P.IsmailN.ZhangX.AgudaB. D.LeeE. J.YuL.et al. (2008). Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE3:e3694. 10.1371/journal.pone.0003694
23
IchaiP.SamuelD. (2008). Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl. 14(Suppl. 2), S67–S79. 10.1002/lt.21612
24
IchaiP.SamuelD. (2011). Epidemiology of liver failure. Clin. Res. Hepatol. Gastroenterol. 35, 610–617.
25
JiF.YangB.PengX.DingH.YouH.TienP. (2011). Circulating microRNAs in hepatitis B virus-infected patients. J. Viral. Hepat. 18, e242–e251. 10.1111/j.1365-2893.2011.01443.x
26
JoplingC. (2012). Liver-specific microRNA-122: biogenesis and function. RNA Biol. 9, 137–142. 10.4161/rna.18827
27
JoplingC. L. (2008). Regulation of hepatitis C virus by microRNA-122. Biochem. Soc. Trans. 36, 1220–1223. 10.1042/BST0361220
28
KimD. J.LinnstaedtS.PalmaJ.ParkJ. C.NtrivalasE.Kwak-KimJ. Y.et al. (2012). Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J. Mol. Diagn. 14, 71–80. 10.1016/j.jmoldx.2011.09.002
29
LeeW. M. (2012). Acute liver failure. Semin. Respir. Crit. Care Med. 33, 36–45. 10.1055/s-0032-1301733
30
KozomaraA.Griffiths-JonesS. (2011). miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39, D152–D157. 10.1093/nar/gkq1027
31
LiL. M.HuZ. B.ZhouZ. X.ChenX.LiuF. Y.ZhangJ. F.et al. (2010). Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 70, 9798–9807. 10.1158/0008-5472.CAN-10-1001
32
LodesM. J.CaraballoM.SuciuD.MunroS.KumarA.AndersonB. (2009). Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE4:e6229. 10.1371/journal.pone.0006229
33
MiskaE. A. (2005). How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev. 15, 563–568. 10.1016/j.gde.2005.08.005
34
MitchellP. S.ParkinR. K.KrohE. M.FritzB. R.WymanS. K.Pogosova-AgadjanyanE. L.et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 105, 10513–10518. 10.1073/pnas.0804549105
35
MoritaK.TaketomiA.ShirabeK.UmedaK.KayashimaH.NinomiyaM.et al. (2011). Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int. 31, 474–484. 10.1111/j.1478-3231.2010.02433.x
36
NegriniM.GramantieriL.SabbioniS.CroceC. M. (2011). microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med. Chem. 11, 500–521.
37
NgE. K.ChongW. W.JinH.LamE. K.ShinV. Y.YuJ.et al. (2009). Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut58, 1375–1381. 10.1136/gut.2008.167817
38
NovellinoL.RossiR. L.BoninoF.CavalloneD.AbrignaniS.PaganiM.et al. (2012). Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs. PLoS ONE7:e31952. 10.1371/journal.pone.0031952
39
QiR.WeilandM.GaoX. H.ZhouL.MiQ. S. (2012). Identification of endogenous normalizers for serum microRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer. Hepatology55, 1640–1642; author reply 1642–1643. 10.1002/hep.25558
40
RennerE. L. (2007). How to decide when to list a patient with acute liver failure for liver transplantation? Clichy or King's College criteria, or something else?J. Hepatol. 46, 554–557. 10.1016/j.jhep.2007.01.009
41
ResnickK. E.AlderH.HaganJ. P.RichardsonD. L.CroceC. M.CohnD. E. (2009). The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 112, 55–59. 10.1016/j.ygyno.2008.08.036
42
RoderburgC.MollnowT.BongaertsB.ElfimovaN.Vargas CardenasD.BergerK.et al. (2012). Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS ONE7:e32999. 10.1371/journal.pone.0032999
43
Sarasin-FilipowiczM.KrolJ.MarkiewiczI.HeimM. H.FilipowiczW. (2009). Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat. Med. 15, 31–33. 10.1038/nm.1902
44
ShiR.ChiangV. L. (2005). Facile means for quantifying microRNA expression by real-time PCR. Biotechniques39, 519–525.
45
SkogJ.WurdingerT.Van RijnS.MeijerD. H.GaincheL.Sena-EstevesM.et al. (2008). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10, 1470–1476. 10.1038/ncb1800
46
Starkey LewisP. J.DearJ.PlattV.SimpsonK. J.CraigD. G.AntoineD. J.et al. (2011). Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology54, 1767–1776. 10.1002/hep.24538
47
TaylorD. D.Gercel-TaylorC. (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110, 13–21. 10.1016/j.ygyno.2008.04.033
48
WangK.ZhangS.MarzolfB.TroischP.BrightmanA.HuZ.et al. (2009). Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci. U.S.A. 106, 4402–4407. 10.1073/pnas.0813371106
49
WangS.QiuL.YanX.JinW.WangY.ChenL.et al. (2012). Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1)-modulated P53 activity. Hepatology55, 730–741. 10.1002/hep.24809
50
XuH.HeJ. H.XiaoZ. D.ZhangQ. Q.ChenY. Q.ZhouH.et al. (2010). Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology52, 1431–1442. 10.1002/hep.23818
51
XuJ.WuC.CheX.WangL.YuD.ZhangT.et al. (2011). Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol. Carcinog. 50, 136–142. 10.1002/mc.20712
52
ZhangY.JiaY.ZhengR.GuoY.WangY.GuoH.et al. (2010). Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin. Chem. 56, 1830–1838. 10.1373/clinchem.2010.147850
53
ZhaoY.SrivastavaD. (2007). A developmental view of microRNA function. Trends Biochem. Sci. 32, 189–197. 10.1016/j.tibs.2007.02.006
54
ZhouJ.YuL.GaoX.HuJ.WangJ.DaiZ.et al. (2011). Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J. Clin. Oncol. 29, 4781–4788. 10.1200/JCO.2011.38.2697
Summary
Keywords
microRNA, extracellular miRNA, miR-122, acute liver failure, spike-in RNA, miRNA quantification
Citation
Elfimova N, Schlattjan M, Sowa J-P, Dienes HP, Canbay A and Odenthal M (2012) Circulating microRNAs: promising candidates serving as novel biomarkers of acute hepatitis. Front. Physio. 3:476. doi: 10.3389/fphys.2012.00476
Received
01 September 2012
Accepted
05 December 2012
Published
21 December 2012
Volume
3 - 2012
Edited by
Heike Bantel, Hannover Medical School, Germany
Reviewed by
Takashi Joh, Nagoya City University Graduate School of Medical Sciences, Japan; Rolf Gebhardt, University of Leipzig, Germany; Heike Bantel, Hannover Medical School, Germany
Copyright
© 2012 Elfimova, Schlattjan, Sowa, Dienes, Canbay and Odenthal.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
*Correspondence: Margarete Odenthal, Laboratory of Molecular Hepatology, Institute for Pathology, University Hospital of Cologne, Kerpener Str. 62, 50924 Koeln, Germany. e-mail: m.odenthal@uni-koeln.de
This article was submitted to Frontiers in Gastrointestinal Sciences, a specialty of Frontiers in Physiology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.